Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case

Published:2016-05-04 Issue:10 Volume:23 Page:767-779
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Deuffic-Burban S.¹²³,Obach D.¹²,Canva V.⁴,Pol S.⁵⁶,Roudot-Thoraval F.⁷,Dhumeaux D.⁸,Mathurin P.³⁴,Yazdanpanah Y.¹²⁹

Affiliation:

1. Inserm; IAME; UMR 1137; Paris France

2. Univ Paris Diderot; Sorbonne Paris Cité; Paris France

3. Univ Lille Inserm; CHU Lille; U995 - LIRIC - Lille Inflammation Research International; Lille France

4. Service des Maladies de l'Appareil Digestif et de la Nutrition; Hôpital Huriez; CHU Lille; Lille France

5. Unité d'hépatologie; Groupe Hospitalier Cochin Hôtel-Dieu; Paris France

6. Inserm U1016; Univ Paris Descartes; Paris France

7. Service Santé Publique; Hôpital Henri Mondor; Créteil France

8. Inserm U955; Hôpital Henri Mondor; Créteil France

9. Service de Maladies Infectieuses et Tropicales; Hôpital Bichat Claude Bernard; Paris France

Funder

Agence Nationale de Recherches sur le Sida et les Hepatites Virales

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12546/fullpdf

Reference40 articles.

1. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives;Welsch;Gut,2012

2. Sofosbuvir for previously untreated chronic hepatitis C infection;Lawitz;N Engl J Med,2013

3. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection;Sulkowski;N Engl J Med,2014

4. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial;Lawitz;Lancet Infect Dis,2013

5. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study;Lawitz;Lancet,2014

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis;Liver International;2024-02-20

2. Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results;Applied Health Economics and Health Policy;2020-07-14

3. Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results;2020-06-23

4. Epidemiology, Use of resources, and Costs of Medical Management of Hepatitis C in Argentina, Colombia, Uruguay, and Venezuela;Value in Health Regional Issues;2019-12

5. Hepatitis C care cascade in HIV patients at an urban clinic in the early direct-acting antiviral era;International Journal of STD & AIDS;2019-06-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3